Cytek Biosciences, Inc. (CTKB) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Cytek Biosciences, Inc. (CTKB:NASDAQ), powered by AI.

Current Price
$4.09
P/E Ratio
-7.9
Market Cap
522M
Sector
Healthcare
What is the Cytek Biosciences, Inc. stock price forecast?

Cytek Biosciences, Inc. is currently trading at $4.09. View real-time AI analysis on Alpha Lenz.

What is Cytek Biosciences, Inc. insider trading activity?

View the latest insider trading data for Cytek Biosciences, Inc. on Alpha Lenz.

What is Cytek Biosciences, Inc.'s P/E ratio?

Cytek Biosciences, Inc.'s P/E ratio is -7.9.

Cytek Biosciences, Inc.

NASDAQ · CTKB
$4.09+0.16(+4.07%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Cytek Biosciences, Inc.'s future dividend policy...
Alpha Chat Insight

Cytek Biosciences, Inc. trades at a P/E of -7.9 (undervalued) with modest ROE of -18.0%.

Ask for details

Company Overview

Cytek Biosciences Inc. is a biotechnology company that specializes in advancing the capabilities of flow cytometry technologies. Its primary function is to develop and deliver transformative, cost-effective products for researchers and clinicians in the life sciences sector. The company is renowned for its full spectrum flow cytometry systems, which allow users to conduct high-parameter cell analysis with higher accuracy and efficiency compared to traditional methods. This technology has significant implications in numerous fields, including immunology, oncology, and stem cell research, thereby supporting efforts in drug discovery, clinical trials, and personalized medicine. Cytek Biosciences Inc.'s offerings play a crucial role in enabling scientific discoveries and advancing public health initiatives. As a prominent player in the biotechnology market, Cytek contributes to pushing the boundaries of what's possible in cellular analysis, fostering breakthroughs that can lead to new therapeutic strategies and medical treatments.

CEODr. Wenbin Jiang Ph.D.
SectorHealthcare
IndustryMedical Devices
Employees688

Company Statistics

FY 2025

Profile

$522.48MMarket Cap
$201.49MRevenue
0.00Shares Out
688Employees

Margins

51.84%Gross
-8.63%EBITDA
-20.04%Operating
-14.81%Pre-Tax
-33.02%Net

Valuation

-7.85P/E
1.53P/B
2.59EV/Sales
-26.18EV/EBITDA
-58.86P/FCF

Growth (CAGR)

7.10%Rev 3Yr
16.76%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-13.85%ROA
-18.05%ROE
-6.11%ROIC

Financial Health

$90.85MCash & Cash Equivalents
$28.95MNet Debt
35.06%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Cytek Biosciences, Inc. (ticker: CTKB) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 688 employees. Market cap is $522M.

The current price is $4.09 with a P/E ratio of -7.85x and P/B of 1.53x.

ROE is -18.05% and operating margin is -20.04%. Annual revenue is $201M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Cytek Biosciences, Inc. (CTKB) Stock Forecast 2026 $4.09 — Price, Financials & Analyst Targets | Alpha Lenz